Amneal Pharmaceuticals, Inc. (AMRX) Thursday said that the U.S. Food and Drug Administration (FDA) has approved its sodium oxybate oral solution which references Jazz Pharmaceutical's Xyrem.
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in individuals aged 7 years and older with narcolepsy.
Amneal had previously been distributing an approved generic of sodium oxybate oral solution in limited quantities.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.